TORNA ALL’ELENCO

Thirty-day clinical outcomes following bioresorbable vascular scaffold implantation in patients presenting with acute coronary syndromes versus stable coronary artery disease: Results from the Italian rai registry in Journal of the American College of Cardiology

2017
ASL Asti

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (16)Vedi tutti...

Moscarella E
Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Ferrarotto, Santa Marta, S. Bambino, Catania, Italy
Varricchio A
Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Ferrarotto, Santa Marta, S. Bambino, Catania, Italy
Ielasi A
Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Ferrarotto, Santa Marta, S. Bambino, Catania, Italy

et alii...

Abstract

BACKGROUND Bioresorbable vascular scaffold (BVS) technology represents a revolutionary concept in interventional cardiology. It appears an attractive alternative to metallic drug-eluting stents and its use is rapidly extending even to complex lesions. However concerns have been raised to an increased risk of scaffold thrombosis (ST) that may be related to procedural factors as well as to patients' characteristics. Acute coronary syndrome (ACS) has shown to increase the risk of drug eluting stent (DES) thrombosis and to date, data on PCI with BVS implantation in patients presenting with acute coronary syndromes (ACS) are still limited. We aimed to investigate the 30 months clinical outcome following BVS implantation in ACS versus stable coronary artery disease (CAD) patients. METHODS RAI (Clinical Trials. gov Identifier: NCT02298413) is an Italian, prospective, multicentre registry not funded by the manufacturer, whose aim is to investigate BVS performance through a 5-year follow-up of all consecutive patients who have undergone successful implantation of 1 or more BVS indifferent lesions subsets. Co-primary end-points were target lesion revascularization (TLR) and BVS definite/probable thrombosis. Secondary endpoint was the occurrence of device-oriented cardiac events (DOCE) including cardiac death, target lesion revascularization and target vessel myocardial infarction. The registry involved 23 centers, was started in October 2012 and the last patient was enrolled in December 2015. Here we report a 30-day clinical comparison between BVS use in ACS versus stable CAD patients. RESULTS Among the 1505 consecutive patients enrolled, 59.5% presented with ACS, of whom 36.5% were ST-elevation myocardial infarctions, while 40.5% with stable angina. Age, male gender and hypertension were more frequent in the stable CAD group; while smoking and history of previous MI were more frequent in the ACS group. All lesions were pre-dilated and no differences between ACS and st

DOI : 10.1016/j.jacc.2017.03.026

Keywords

register; optical coherence tomography; multicenter study; male; major clinical study; intravascular ultrasound; implantation; hypertension; human; heart death; gender; follow up; female; drug eluting stent; controlled study; controlled clinical trial; clinical trial; clinical outcome; animal model; acute coronary syndrome; fibrinogen receptor; endogenous compound; bivalirudin; smoking; ST segment elevation myocardial infarction; stable angina pectoris; stent thrombosis; target lesion revascularization;